BEIJING, Jan. 11 (Xinhua) China benchmark prices for spot interbank gold transactions were lower Monday, according to the China Foreign Exchange Trade System
As the Focus on Psychedelic Stocks Increases, So Do the Valuations The only companies that have Phase 2 clinical trials now are Compass Pathways, Mind Medicine, Cybin, and Mydecine Innovations.
With so many new IPOs and companies launching in the psychedelic industry it s important to fully evaluate the major factors of success or failure in the industry. There are various steps that companies take to have a drug approved and to successfully complete them it takes years and tens of millions of dollars. The further ahead a company moves in the approval process, the more valuable the company becomes, and that is why there is so much excitement for Compass Pathways (CMPS) . Institutional and retail investors are in a frenzy to get a position. The company is in Phase 2b and has received a Breakthrough Therapy designation from the FDA, meaning that their therapy has the potential to be more effective than available medications.